(Source: Enanta Pharmaceuticals Inc) Enanta Announces JAMA Publication of Results from AbbVie's Study of VIEKIRA PAK™ (ombitasvir, paritaprevir, ritonavir tablets; dasabuvir tablets) in Chronic Hepatitis C Patients with HIV-1 Co-Infection (TURQUOISE-I) In adult patients co-infected with genotype 1 (GT1) hepatitis C virus (HCV)human immunodeficiency virus type 1 (HIV-1), using VIEKIRA PAK with ribavirin (RBV), (TURQUOISE-I Study) demonstrated sustained virologic response rates 12 weeks post-treatment (SVR12) of 94 percent with 12 weeks of treatment91 percent with 24 weeks of treatment, respectively Regimen contains Enanta's lead protease inhibitor, paritaprevir Additional sub-analyses of...
↧